Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion
Related Experiment Video
Updated: Sep 27, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
Minoru Narita1, Keisuke Mizuo, Hirokazu Mizoguchi
1Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Shinagawa-ku, Tokyo 142-8501, Japan.
Abstract:
The aim of the present study was to investigate the role of dopamine D(3) receptors in the rewarding effect and hyperlocomotion induced by a prototypical mu-opioid receptor agonist morphine using dopamine D(3) receptor knock-out mice. The mu-opioid receptor in the brain determined by the [tylosil-3,5-(3)H(N)]-[D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin binding assay was not significantly changed by a deletion of the dopamine D(3) receptor gene. Furthermore, we found that no significant differences in G-protein activation by morphine in the limbic forebrain and lower midbrain were noted between the two genotypes. These results suggest that the function of the mu-opioid receptor itself was not affected by a deletion of the dopamine D(3) receptor gene. To ascertain the morphine-induced rewarding effect in both genotypes, the conditioned place preference paradigm was performed. Deletion of the dopamine D(3) receptor gene resulted in a remarkable enhancement of the morphine-induced rewarding effect. Furthermore, knock-out mice with deletions of the dopamine D(3) receptor revealed a dramatic potentiation of morphine-induced hyperlocomotion. Under these conditions, a loss of the dopamine D(3) receptor gene had no effect on the basal levels of dopamine and the increased dopamine turnover by morphine in the limbic forebrain. These findings provide further evidence that dopamine D(3) receptor contributes to the postsynaptically negative modulation of the mesolimbic dopaminergic pathway that is associated with the rewarding effect and hyperlocomotion through the stimulation of mu-opioid receptors induced by morphine in the mouse.
Insights
Mice lacking dopamine D(3) receptors showed enhanced morphine reward and activity. Dopamine D(3) receptors negatively modulate the brain's response to morphine, affecting reward and locomotion.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Morphine, a mu-opioid agonist, produces rewarding effects and hyperlocomotion.
- Dopamine D(3) receptors are implicated in modulating neurotransmitter systems.
- The precise role of dopamine D(3) receptors in morphine's effects remains unclear.
Purpose of the Study:
- To investigate the role of dopamine D(3) receptors in morphine-induced reward and hyperlocomotion.
- To determine if dopamine D(3) receptor deletion affects mu-opioid receptor function.
Main Methods:
- Utilized dopamine D(3) receptor knock-out mice and wild-type littermates.
- Assessed mu-opioid receptor binding and G-protein activation.
- Employed the conditioned place preference paradigm to measure reward.
- Measured dopamine levels and turnover in the limbic forebrain.
Main Results:
- Dopamine D(3) receptor deletion did not alter mu-opioid receptor binding or G-protein activation by morphine.
- Mice lacking dopamine D(3) receptors exhibited significantly enhanced morphine-induced rewarding effects.
- Dopamine D(3) receptor knock-out mice showed potentiated morphine-induced hyperlocomotion.
- Basal dopamine levels and morphine-induced dopamine turnover were unaffected by dopamine D(3) receptor deletion.
Conclusions:
- Dopamine D(3) receptors negatively modulate the mesolimbic dopaminergic pathway.
- These receptors play a crucial role in regulating the rewarding and locomotor effects of morphine.
- Targeting dopamine D(3) receptors may offer novel therapeutic strategies for opioid addiction.
More Related Videos
Related Concept Videos
Opioid Receptors: Overview
Drug Abuse and Addiction: Pharmacological Phenomena
Analgesia and Pain Management
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Opioid Analgesics: Synthetic and Semisynthetic Opioids

